Impact of apolipoprotein A5 variants on statin treatment efficacy

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 945-950

  Hubacek, Jaroslav A ^a,b,c   Adamkova, Vera ^a,c   Prusikova, Martina ^b   Snejdrlova, Michaela ^b   Hirschfeldova, Katerina ^b   Lanska, Vera ^a   Ceska, Richard ^b   Vrablik, Michal ^b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

Apolipoprotein A5; Cholesterol; Effect; Pharmacogenetics; Polymorphism; Statin; Triglyceride

Indexed keywords

ADENINE; APOLIPOPROTEIN A5; APOLIPOPROTEIN E; ATORVASTATIN; CYTOSINE; GUANINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; THYMINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENOMICS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; AGED; ALLELES; APOLIPOPROTEINS A; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COHORT STUDIES; CZECH REPUBLIC; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FORECASTING; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 69049104447     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.17     Document Type: Article

References (23)

1. Libby P: The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46(7), 1225-1228 (2005).
2. Schmitz G, Langmann T: Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharm. 44(2), 75-89 (2006).
3. Mangravite LM, Krauss RM: Pharmacogenetics of statin response. Curr. Opin. Lipidol. 18(4), 409-419 (2007).
4. Pennacchio LA, Olivier M, Hubacek JA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294(5540), 169-173 (2001).
5. Hubacek JA, Skodova Z, Lanska V, Adamkova V: Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians. Exp. Clin. Cardiol. 13(3), 129-132 (2008).
6. Lai CQ, Demissie S, Cupples LA et al.: Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45(11), 2096-2105 (2004).
7. Hubacek JA: Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin. Chem. Lab. Med. 43(9), 897-902 (2005).
8. Calandra S, Priore Oliva C, Tarugi P, Bertolini S: APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr. Opin. Lipidol. 17(2), 122-127 (2006).
9. Hubáček JA, Škodová Z, Adámková V, Lánská V, Poledne R: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infafction. Clin. Genet. 65(2), 126-130 (2004).
10. Szalai C, Keszei M, Duba J et al.: Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 173(1), 109-114 (2004).
11. Tai ES, Ordovas JM: Clinical significance of apolipoprotein A5. Curr. Opin. Lipidol. 19(4), 349-354 (2008).
12. Dorfmeister B, Zeng WW, Dichlberger A et al.: Effects of six APOA5 variants. identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler. Thromb. Vasc. Biol. 28(10), 1866-1871 (2008).
13. Hubacek JA, Škodová Z, Adámková V, Lánská V, Pitha J: APOA5 variant Ser19Trp influences a decrease of the total cholesterol in a males 8 years cohort. Clin. Biachem. 39(2), 133-136 (2006).
14. Hubacek JA, Bohuslavova R, Škodová Z, Pitha J, Bobkova D, Poledne R: Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change. Clin. Chem. Lab. Med. 45(3), 316-320 (2007).
15. Lai CQ, Corella D, Demissie S et al.: Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: The Framingham Heart Study. Circulation 113(17), 2076-2070 (2006).
16. Lai CQ, Arnett DK, Corella D et al.: Fenofibrate efect on triglyceride and postprandial response of apolipoprotein A5 variants. The GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27(6), 1417-1425 (2007).
17. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R: Sex-specific effect of APOAV variant (Va1153>Met) on plasma levels of high-density lipoprotein cholesterol. Metabolism 54(12), 1632-1635 (2005).
18. Dallinga-Thie GM, van Tol A, Hattori H et al.: Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 49(7), 1505-1511 (2006).
19. Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE: APOA5 genotype, plasma apolipoprotein AV and triglyceride levels and the prospective risk of Type 2 diabetes: results from the Northwick Park Hearth Study II. Diabetologia 49(10), 2337-2340 (2006).
20. O'Brien PJ, Alborn WE, Sloan JH et al.: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51(2), 351-359 (2005).
21. Bai L, Yhao S, Huang X, Yhang Q: Upregulating APOAV expression by statins via PPAR-α activated pathway possibly contributes to their triglyceride-lowering effect. Bioscience Hypotheses 1(6), 292-294 (2008).
22. Nieminen T, Kähönen M, Viiri LE, Grönroos P, Lehtimäki T: Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 9(10), 1475-1486 (2008).
23. Novembre J, Johnson T, Bryc K et al.: Genes mirror geography within Europe. Nature 456(6), 98-101 (2008).